What exactly is Tandem Mobi Tubeless?
Mobi Tubeless is not a new pump - it is a new way to wear the existing Tandem Mobi pump.
The current Mobi is the smallest tubed insulin pump on the market. The Tubeless version replaces the tubing with a patch-style infusion set that the pump itself clips into. This makes the system effectively tubeless - the pump sits directly on the skin, much like Omnipod.
It's a smart move: people who already own a Mobi do not need to buy a new device. They only need a new type of infusion set to start wearing their existing pump in tubeless mode.
Seven days with one set - this is the key difference
Tandem Mobi Tubeless would be far less interesting without the technology behind it. The company has developed SteadiSet - an infusion set cleared by the FDA for up to 7 days of wear.
That is more than twice as long as Omnipod 5's 3-day wear period. In practice, that means:
around 52 set changes per year instead of more than 120,
fewer interruptions to insulin delivery,
fewer opportunities for infections and infusion-site problems,
more convenience, especially when traveling or working.
There is one catch: the reservoir holds 200 units of insulin. If your daily dose is above 30-35 units, the insulin will run out before the full seven days are over. Tandem expects users to be able to replace the cartridge without removing the patch, although that still adds an extra step.
SteadiSet is expected to reach the market in the first half of 2027.
How does it work in practice?
The patch is applied with an applicator similar to those used for CGM sensors. Once it is attached to the skin, the pump is inserted into it - a new side-clip system is designed to make this easier.
When the insulin cartridge needs replacing, the pump can be removed from the patch, fitted with a new cartridge, and clipped back into place without changing the infusion site.
Importantly, tubeless is an option, not a requirement. If you prefer the traditional setup with tubing, you can keep using it.
Control-IQ+ - the same system used in the t:slim X2
Mobi Tubeless uses the same software platform as Tandem's other pumps - Control-IQ+. It is a hybrid automated insulin delivery system that:
predicts and helps prevent hyperglycemia and hypoglycemia,
automatically adjusts insulin delivery,
works with Dexcom G6 and G7 sensors.
Control-IQ+ was recently approved in Europe under the CE Mark for use during pregnancy in women with type 1 diabetes and in people with type 2 diabetes. In the 2IQP study involving more than 300 people with type 2 diabetes, Control-IQ+ produced an average HbA1c reduction of 0.9%, compared with 0.3% in the control group. Among people starting with HbA1c ≥9%, the reduction reached as much as 2.3%.
Smartphone control - yes!
Mobi, in both its tubeless and traditional versions, can be controlled entirely from a smartphone app. This is one of its strongest advantages - the pump is so small that it does not even have its own screen.
The app works on both iOS and Android.
Nightscout, Loop, AAPS - what about integrations?
Tandem does not provide an official, straightforward way to send data to Nightscout. However, the community has developed tconnectsync, a tool that synchronizes data from Tandem Source, formerly t:connect, with Nightscout. It works with both the t:slim X2 and Mobi.
As for systems such as Loop, Trio, or AndroidAPS, integration work is ongoing, but I would not expect official Tandem support anytime soon. The company is clearly focused on its own ecosystem.
When will Tandem Mobi Tubeless be available in Poland?
This is probably the most important question, and unfortunately there is no simple answer.
The facts:
Tandem submitted a 510(k) application to the FDA in the second quarter of 2026.
Expected clearance: second half of 2026.
In Europe, Tandem Mobi in its tubed version is expected to launch in selected countries in the second half of 2026.
The tubeless version is planned for 2027.
What does that mean for Poland?
For now, the manufacturer has not announced a Polish launch date. Tandem entered the UK, Switzerland, and Austria this year, plans to launch in France before the end of 2026, and is targeting additional European markets in 2027. Poland is not mentioned in those plans.
A realistic scenario is 2027-2028, if it happens at all. That also assumes a distributor becomes available and the Polish National Health Fund decides to reimburse the system.
How much will it cost?
Tandem has not announced pricing for the tubeless version. For comparison, the current Mobi costs around $6 035 without insurance in the US. European pricing will be different, but I would not expect it to be cheaper.
Tandem is working on a PayGo model that would let users pay for the pump through a subscription-style system instead of making a large upfront payment. That could improve access, although by Polish standards it is still likely to be expensive.
Summary - is it worth waiting for?
Tandem Mobi Tubeless looks like a sensible evolution rather than a revolution. Tandem is taking an existing pump, adding a patch-based wearing option and a seven-day infusion set. I think that is the right strategy: it improves what already works instead of forcing users into an entirely new platform.
Key takeaways:
Seven days with one infusion set is the biggest advantage - more than twice as long as Omnipod.
It is still the same pump - it runs Control-IQ+ and can be worn with or without tubing.
Polish launch date? None for now. Realistically, 2027-2028.
Price - probably high, although PayGo could soften the upfront cost.
Is it a "game changer"? I would not call it that. It looks more like a meaningful step in the right direction: longer wear time and more flexibility without leaving Tandem's ecosystem. For existing Mobi users in particular, that approach makes a lot of sense.
I'll keep following the topic and update this post when more concrete information about Poland becomes available.
Sources:
